The Innovative Medicines Initiative (IMI) launches its 13th call30-11-2017
The Innovative Medicines Initiative (IMI) has launched a new Call for proposals covering diabetes, antimicrobial resistance, neurodegenerative diseases, cancer, and medicines safety during pregnancy and breastfeeding, to name just a few.
The total budget of the Call is EUR 223 million, around half of which comes from the EU’s Horizon 2020 programme, and half of which comes from EFPIA companies and IMI Associated Partners. All topic texts, Call documentation and details of how to apply can be found on the IMI website – www.imi.europa.eu – which also includes pages with advice for applicants and guidance on how to find project partners.
Why apply? IMI Calls for proposals represent an excellent opportunity for researchers to take part in ground-breaking collaborative projects that aim to deliver tangible benefits for patients. Scientists from academia, industry, SMEs, mid-sized companies, hospitals and patients’ organisations are encouraged to get involved in our projects. Our success stories page offers a glimpse of the kinds of things IMI projects can achieve, and includes testimonials from project participants.
Deadline for submitting short proposals: 28 February 2018
Questions may be directed directly to IMI at e-mail email@example.com
The Danish member of the IMI States Representatives Group is Kim Kryger, Head of section, EuroCenter, NCP for Health and IMI, Programme Committee for Health at e-mail firstname.lastname@example.org